HLA-A*26:01 antigen

GenBank X93881

Also Known As:

HLA A*2601; HLA-A*2601

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*26:01 antigen: 5
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*26:01 antigen: 5
  - Membrane Proteins: 10078
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*26:01 antigen: 5
Biological Factors: 2472
- Antigens: 143924
  - Surface Antigens: 5813
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-A Antigens: 2452
        HLA-A*26:01 antigen: 5
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*26:01 antigen: 5
  - Isoantigens: 1221
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-A Antigens: 2452
        HLA-A*26:01 antigen: 5
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*26:01 antigen: 5

Experts

1.	Akiyama, Goichi: 1 article (11/2015)
2.	Aoyagi, Ranko: 1 article (11/2015)
3.	Inaba, Mayumi: 1 article (11/2015)
4.	Kohno, Hideo: 1 article (11/2015)
5.	Kuroyanagi, Kana: 1 article (11/2015)
6.	Okano, Kiichiro: 1 article (11/2015)
7.	Sakai, Tsutomu: 1 article (11/2015)
8.	Tsuneoka, Hiroshi: 1 article (11/2015)
9.	Itoh, Kyogo: 1 article (11/2009)
10.	Komatsu, Nobukazu: 1 article (11/2009)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2003 - "We assessed cytotoxic activities and cytokine production of these CTL clones reacting against cancer cell lines that stably or transiently expressed the HLA-A2601 gene. " 11/01/2009 - "In addition, one peptide with HLA-A24-binding activity could bind to HLA-A2601 and induced HLA-A26-restricted cytotoxic T lymphocytes from HLA-A2601-, -A2602-, or -A2603-positive prostate cancer patients against HLA-A2603-positive cancer cells. " 11/01/2009 - "These three peptides induced HLA-A26-restricted cytotoxic T lymphocytes from HLA-A2601-, -A2602-, or -A2603-positive prostate cancer patients against HLA-A2601- and HLA-A2603-positive cancer cells in CD8-dependent and peptide-specific manners. " 11/01/2009 - "The HLA-A2601-crossbinding activity of 24 peptides currently under clinical trial as vaccines for HLA-A2, -A24, or HLA-A3 supertype-positive cancer patients was evaluated by stabilization assay. "
2.	Vaccinia 05/31/2005 - "Analysis using HIV-1 recombinant vaccinia-infected C1R-A2601 cells indicated that these four peptides were HIV-1 epitopes endogenously presented by HLA-A2601. "
3.	Prostatic Neoplasms (Prostate Cancer) 11/01/2009 - "In addition, one peptide with HLA-A24-binding activity could bind to HLA-A2601 and induced HLA-A26-restricted cytotoxic T lymphocytes from HLA-A2601-, -A2602-, or -A2603-positive prostate cancer patients against HLA-A2603-positive cancer cells. " 11/01/2009 - "These three peptides induced HLA-A26-restricted cytotoxic T lymphocytes from HLA-A2601-, -A2602-, or -A2603-positive prostate cancer patients against HLA-A2601- and HLA-A2603-positive cancer cells in CD8-dependent and peptide-specific manners. "
4.	Pancreatic Neoplasms (Pancreatic Cancer) 05/01/2003 - "We have generated HLA-A2601-restricted CD8+ CTL clones against an autologous pancreatic cancer cell line. " 05/01/2003 - "These CTL clones recognized 4 of 10 allogeneic pancreatic cancer cell lines and a gallbladder cancer cell line in the context of HLA-A2601. " 05/01/2003 - "Analysis of a shared pancreatic cancer antigen recognized by an HLA-A*2601-restricted cytotoxic T-lymphocyte clone."
5.	Melanoma (Melanoma, Malignant) 11/01/2005 - "We identified three previously unknown peptides processed from melanosomal proteins tyrosinase (presented by HLA-A()2601 and -B()3801) and gp100 (presented by HLA-B(*)07021) and five neoantigens generated by somatic point mutations in the patient's melanoma. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	HLA-B Antigens (HLA-B)
3.	Cytokines
4.	HLA-A3 Antigen (HLA A3 Antigen)
5.	HLA-A2 Antigen (HLA A2 Antigen)
6.	Vaccines
7.	Monophenol Monooxygenase (Tyrosinase)
8.	Proteins (Proteins, Gene)
9.	Antigens
10.	Epitopes